Polyrizon Provides 2025 and Recent Highlights

Rhea-AI Summary

Polyrizon (Nasdaq: PLRZ) closed 2025 with approximately $17.5 million in cash, a debt-free balance sheet and multiple preclinical and regulatory milestones. Key actions include an FDA Pre-Submission for PL-14 (NASARIX™), a Pre-RFD for PL-16, GMP manufacturing of clinical material, and a Q2 2026 CRO study start.

The company reported positive preclinical data for an intranasal naloxone hydrogel, successful intranasal delivery for PL-14, manufacturing upscaling progress, and non-binding initiatives to explore investments in private aviation and eVTOL drone technologies.

Positive

• Cash and cash equivalents: $17.5M as of Dec 31, 2025
• Debt-free balance sheet maintained at year-end 2025
• FDA Pre-Submission meeting completed for PL-14 (NASARIX) clinical strategy
• Pre-RFD submitted to FDA for PL-16 viral blocker
• GMP manufacturing of clinical trial material initiated with Eurofins CDMO
• Preclinical results: enhanced deposition for naloxone hydrogel; PL-14 upscaling achieved

Negative

• Preclinical-stage company: no human clinical data yet
• Planned clinical studies dependent on future FDA approvals and funding
• Exploratory, non-binding investment initiatives add strategic uncertainty

Key Figures

Cash & equivalents: $17.5 million Operating loss 2025: $6.249 million Operating loss 2024: $1.302 million +5 more

8 metrics

Cash & equivalents $17.5 million As of December 31, 2025 per business update

Operating loss 2025 $6.249 million Year ended December 31, 2025 (Form 20-F)

Operating loss 2024 $1.302 million Year ended December 31, 2024 (Form 20-F)

Accumulated deficit $8.4 million As of December 31, 2025 (Form 20-F, approximate)

Ordinary shares out. 1,608,266 shares As of December 31, 2025 (Form 20-F)

Cash balance $1.3M cash, $16.2M deposits As of December 31, 2025 (Form 20-F)

Shelf registration size $50,000,000 Form F-3 shelf capacity for future offerings

Colugo stake MOU Up to $6,000,000 Potential acquisition of up to 20% of Colugo Systems

Market Reality Check

Price: $13.75 Vol: Volume 21,737 is 0.68x th...

low vol

$13.75 Last Close

Volume Volume 21,737 is 0.68x the 20-day average 31,945, indicating subdued trading interest before this update. low

Technical Shares at $14.23 are trading above the 200-day MA of $8.59, reflecting a pre-existing uptrend into this news.

Peers on Argus

PLRZ gained 4.79% with 3 close biotech peers (ENSC, SILO, SXTP) also up between ...

2 Up 3 Down

PLRZ gained 4.79% with 3 close biotech peers (ENSC, SILO, SXTP) also up between 1.23% and 5.2%, suggesting a supportive sector backdrop alongside company-specific headlines.

Historical Context

5 past events · Latest: Mar 24 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 24	Strategic MOU	Positive	-5.0%	Non-binding MOU to buy up to 20% of eVTOL drone firm Colugo.
Mar 17	Clinical support deal	Positive	-4.2%	Agreement with leading preclinical CRO for ISO 10993 GLP biocompatibility studies.
Mar 10	GMP CTM milestone	Positive	-0.1%	Successful GMP manufacturing of clinical trial material batch with Eurofins CDMO.
Feb 26	Naloxone data	Positive	+1.1%	Preclinical naloxone nasal formulation showing superior nasal deposition versus reference.
Feb 17	Branding launch	Positive	+0.4%	Launch of NASARIX™ brand and positioning as medical device with planned trials.

Pattern Detected

Recent positive operational updates have often coincided with flat-to-negative next-day price reactions, despite constructive clinical and strategic milestones.

Recent Company History

Over recent months, Polyrizon has advanced its intranasal platform with GMP clinical material, a preclinical CRO agreement, and strong naloxone deposition data, while also unveiling the NASARIX™ brand. A non-binding MOU to acquire up to a 20% stake in Colugo for up to $6,000,000 added a diversification angle. Market reactions have been mixed, with several positive clinical and strategic updates followed by modest declines, framing today’s broad 2025 progress update within a pattern of cautious investor response.

Regulatory & Risk Context

Active S-3 Shelf · $50,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-07

$50,000,000 registered capacity

An effective Form F-3 shelf filed on Nov 7, 2025 allows Polyrizon to offer up to $50,000,000 in securities (ordinary shares, warrants, units) over time, providing capital-raising flexibility for corporate and development needs while introducing potential future equity dilution.

Market Pulse Summary

This announcement underscores Polyrizon’s transition from preclinical work toward human studies, bac...

Analysis

This announcement underscores Polyrizon’s transition from preclinical work toward human studies, backed by $17.5 million in cash and a debt‑free balance sheet as of year‑end 2025. Key steps include an FDA pre‑submission meeting for PL‑14, a Pre‑RFD for PL‑16, GMP clinical material, and positive naloxone hydrogel data. Form 20‑F shows a $6.249 million 2025 operating loss and an accumulated deficit of about $8.4 million, while a $50,000,000 shelf provides financing flexibility but also future dilution risk.

Key Terms

gmp manufacturing, clinical trial material, pre-submission meeting, cdmo, +3 more

7 terms

gmp manufacturing technical

"Announced GMP manufacturing of Clinical Trial Material with Eurofins CDMO"

GMP manufacturing, or Good Manufacturing Practice, is a set of strict guidelines that ensure products, especially medicines and health-related items, are consistently produced and controlled to meet quality standards. For investors, it signifies that a company follows high-quality processes, reducing risks of defects or contamination, which can impact product safety and market trust. This adherence helps ensure the reliability and reputation of the products in the marketplace.

clinical trial material medical

"Announced GMP manufacturing of Clinical Trial Material with Eurofins CDMO"

Clinical trial material consists of the drugs, vaccines, or medical products used in testing new treatments on patients to assess their safety and effectiveness. These materials are critical because they represent the actual products being evaluated, and their development, quality, and availability can impact a company's progress and potential future sales—making them important to investors watching pharmaceutical and biotech companies.

pre-submission meeting regulatory

"Completed a productive FDA Pre-Submission Meeting for the PL-14 (NASARIX™)"

A pre-submission meeting is a planned discussion between a company and a regulatory agency to review plans and data before the company formally files for product approval. It matters to investors because the meeting can reveal what additional tests or information regulators will require, helping reduce surprise delays or costs—think of it like showing a building inspector your blueprints before applying for a construction permit to catch problems early.

cdmo technical

"Announced GMP manufacturing of Clinical Trial Material with Eurofins CDMO"

A contract development and manufacturing organization (CDMO) is a company that provides specialized services to help develop and produce pharmaceutical products for other businesses. Think of it as a contract factory that takes a company's recipe and makes the product on their behalf. For investors, CDMOs are important because they support the growth of pharmaceutical companies and can be key partners in bringing new medicines to market.

cro technical

"Signed an agreement with a leading global Preclinical CRO to support"

CRO stands for Contract Research Organization, a company that helps pharmaceutical and biotech firms manage and carry out clinical trials to test new medicines. For investors, CROs are important because they enable drug companies to develop new treatments more efficiently, potentially accelerating the path to market and affecting the company's growth prospects and success.

preclinical medical

"Reported positive preclinical results for the intranasal Naloxone Hydrogel program"

Preclinical describes the stage of drug or medical-product development when researchers test a candidate in the lab and in animals to see if it is safe, reaches intended targets, and shows basic effectiveness before any human trials begin. For investors, preclinical status signals an early, higher‑risk opportunity where positive lab results can increase value but significant work, time, and regulatory hurdles remain — like proofing a prototype in a workshop before road testing.

mucoadhesion medical

"Naloxone Hydrogel program, demonstrating enhanced nasal deposition and mucoadhesion"

Mucoadhesion is the ability of a drug, medical device or formulation to stick to mucous membranes lining the nose, mouth, throat, eyes or gut, using materials that adhere to wet tissue. For investors it matters because mucoadhesive products can deliver medicine more reliably, extend how long a drug acts, reduce dosing frequency and improve patient convenience—features that can increase a product’s effectiveness, market appeal and commercial value.

AI-generated analysis. Not financial advice.

Company Concluded 2025 with Robust Cash Position, Debt-Free Balance Sheet and Significant Pipeline Achievements

Raanana, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, provided 2025 and recent a business update.

"Polyrizon has delivered significant progress across its innovative nasal programs, including key regulatory advancements with the FDA, preparation for potential human clinical trials, and valuable medical collaborations, all powered by a strong cash position and a debt-free balance sheet,” said Tomer Izraeli, chief executive officer of Polyrizon.

Key Highlights of Polyrizon’s Achievements in 2025 and Recent Highlights:

• As of December 31, 2025, the Company’s cash and cash equivalents totaled approximately $17.5 million.
• Completed a productive FDA Pre-Submission Meeting for the PL-14 (NASARIX™) Allergy Blocker, discussing clinical development strategy and potential human trials.
• Submitted a Pre-Request for Designation (Pre-RFD) to the FDA for the PL-16 Viral Blocker.
• Announced GMP manufacturing of Clinical Trial Material with Eurofins CDMO in preparation for U.S. clinical studies.
• Signed an agreement with a leading global Preclinical CRO to support the clinical development pathway, with studies expected to commence in Q2 2026.
• Reported positive preclinical results for the intranasal Naloxone Hydrogel program, demonstrating enhanced nasal deposition and mucoadhesion.
• Achieved successful intranasal delivery results for PL-14 and completed a key manufacturing upscaling milestone for the nasal spray platform.
  
  

In addition, the Company completed the branding process for its allergy blocker under the name NASARIX™, reported encouraging preclinical data across multiple programs and announced non-binding initiatives to explore potential revenue-generating investment opportunities in high-growth sectors, including potential stakes in private aviation and advanced eVTOL drone technologies, while maintaining full financial flexibility thanks to its strong cash reserves and debt-free status.

About Polyrizon

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the timing and progress of its clinical trials and exploring potential revenue-generating investment opportunities in high-growth sectors, including potential stakes in private aviation and advanced eVTOL drone technologies. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 25, 2026 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.

Contacts:

Michal Efraty

Investor Relations

IR@polyrizon-biotech.com

FAQ

How much cash did Polyrizon (PLRZ) report as of December 31, 2025?

Polyrizon reported approximately $17.5 million in cash and cash equivalents as of December 31, 2025. According to the company, this cash position underpins near-term operations while clinical and regulatory work progresses.

What regulatory progress did Polyrizon (PLRZ) announce for PL-14 NASARIX in 2025?

Polyrizon completed an FDA Pre-Submission meeting for PL-14 (NASARIX) to discuss clinical strategy and potential human trials. According to the company, the meeting covered trial design and regulatory expectations ahead of clinical initiation.

Has Polyrizon (PLRZ) begun manufacturing clinical material for U.S. studies?

Yes. Polyrizon announced GMP manufacturing of clinical trial material with Eurofins CDMO in preparation for U.S. clinical studies. According to the company, this supports planned submissions and future dosing for human trials.

When will Polyrizon (PLRZ) start preclinical studies with its new CRO partner?

Polyrizon expects studies with a leading global preclinical CRO to commence in Q2 2026. According to the company, the agreement is intended to support the clinical development pathway for its nasal programs.

What preclinical results did Polyrizon (PLRZ) report for the naloxone hydrogel program?

Polyrizon reported positive preclinical data showing enhanced nasal deposition and mucoadhesion for its naloxone hydrogel. According to the company, these results support improved intranasal delivery versus prior formulations.

What is the significance of Polyrizon (PLRZ) being debt-free for investors?

Being debt-free means Polyrizon carries no reported debt and has financial flexibility for near-term development. According to the company, the strong cash position and lack of debt support ongoing preclinical and regulatory activities.